Molybdenum-99 Market : Global Industry Analysis and Opportunity Assessment, 2036
The Molybdenum-99 Market is Segmented by Isotopic Application (SPECT, Gamma Camera) and End User (Hospitals, Diagnostic Centers). Forecast for 2025 to 2035.
- Industry Size (2025): USD 5.17 Bn
- Forecast (2035): USD 7.74 Bn
- CAGR (2025 to 2035): 4.6%
Molybdenum-99 Market Size, Market Forecast and Outlook By FMI
The molybdenum-99 market is expected to expand from USD 5.17 billion in 2025 to USD 7.74 billion by 2035. The market is anticipated to register a 4.6% CAGR during the forecast period. SPECT imaging is likely to lead isotopic application with an 80.0% share, while hospitals are expected to advance at a 4.8% CAGR through 2035.
Summary of the Molybdenum-99 Market
- Demand and Growth Drivers
- Nuclear medicine procedure volumes are expected to keep molybdenum-99 demand active across diagnostic imaging centers.
- Technetium-99m use is likely to support repeat isotope demand because it remains central to SPECT imaging.
- Domestic isotope production programs are anticipated to improve supply security in countries reducing reactor dependence.
- Product and Segment View
- SPECT imaging is expected to lead isotopic application due to its broad use in cardiac, bone, and cancer diagnostics.
- Hospitals are likely to remain the main end user as nuclear imaging supports routine diagnosis and treatment planning.
- Gamma camera use is anticipated to support continued isotope demand across established nuclear medicine workflows.
- Geography and Competitive Outlook
- The United States is expected to lead country-level expansion as domestic non-HEU production receives policy support.
- Japan is likely to record steady expansion as nuclear imaging demand rises across cancer and cardiovascular diagnosis.
- Companies with reactor-free production capability and reliable isotope distribution are anticipated to gain stronger buyer confidence.
- Analyst Opinion
- Sabyasachi Ghosh, Principal Consultant for Healthcare at FMI, suggests, “The molybdenum-99 market is shifting toward supply resilience as healthcare systems reduce dependence on aging reactor networks. SPECT imaging will remain central to demand, while non-HEU and accelerator-based production routes are likely to shape procurement confidence.”
- Molybdenum-99 Market Value Analysis
- The molybdenum-99 market is moving from reactor-dependent supply toward more secure isotope production planning.
- Industry value is likely to rise as technetium-99m remains essential for high-volume nuclear diagnostic procedures.
- Product uptake is expected to improve as hospitals and diagnostic centers expand SPECT and SPECT/CT capabilities.
- Spending is anticipated to be supported by chronic disease diagnosis, aging populations, and domestic radioisotope investments.
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 5.17 billion |
| Projected Market Size in 2035 | USD 7.74 billion |
| CAGR (2025 to 2035) | 4.6% |
Analyzing Molybdenum-99 Market by Top Investment Segments
The molybdenum-99 market is segmented by isotopic application, end user, and region. By isotopic application, the market includes SPECT and gamma camera modalities. In terms of end user, key segments encompass hospitals and diagnostic centers. By region, the market spans North America, Latin America, East Asia, South Asia & Pacific, Eastern Europe, Western Europe, and the Middle East & Africa.
By Isotopic Application, SPECT Imaging Expected to Account for Consistent Usage
SPECT (Single Photon Emission Computed Tomography) imaging continues to be one of the primary applications in the molybdenum-99 market, largely due to its compatibility with technetium-99m, which is derived from Mo-99.
This modality is commonly used in nuclear medicine procedures for cardiac, bone, and cancer diagnostics. The technique supports dynamic imaging of physiological functions, aiding in early detection and disease monitoring. Healthcare systems are adopting hybrid platforms such as SPECT/CT, and Tc-99m remains widely accessible and cost-aligned for multiple clinical settings. The demand for functional imaging is expected to support SPECT’s usage throughout the forecast period.
| Isotopic Application | Market Share (2025) |
|---|---|
| SPECT Imaging | 80% |
By End User, Hospitals Likely to See Steady Demand Growth
Hospitals represent a significant share of molybdenum-99 usage due to the integration of nuclear imaging into routine diagnostics and treatment planning. These institutions are equipped to perform procedures involving Tc-99m tracers, supporting use in cardiology, oncology, neurology, and orthopedic applications.
In addition to imaging, hospitals often participate in clinical research and educational programs that rely on Mo-99-based technologies. Diagnostic centers also contribute to market growth, especially in urban and semi-urban areas, although their infrastructure and tracer demand are generally scaled to outpatient throughput.
| End User | CAGR (2025 to 2035) |
|---|---|
| Hospitals | 4.8% |
Challenges and Opportunities
Challenges
Reactor Dependence and Supply Chain Vulnerability
The molybdenum-99 (Mo-99) market suffers challenges due to its dependence on old nuclear reactors, a significant portion of which are being decommissioned/ significantly requiring infrastructure upgrades. Much of global supply depends on a small number of producers, generating supply bottlenecks and geopolitical risks.
Due to the short half-life of Mo-99 (~66 hours), the transportation, distribution, and inventory of Mo-99 is challenging and can incur additional costs and waste in the event of delays. On top of all this, regulatory issues regarding nuclear waste, reactor safety and HEU (HEU) use continue to hold back growth.
Opportunities
Growth in Non-Reactor Production, Radiopharmaceutical Demand, and Technetium-99m Imaging
Mo-99 is still vital for creating Technetium-99m (Tc-99m)-used in almost 80% of all nuclear medicine diagnostic imaging examinations, especially cardiac, bone, and cancer diagnostics. Novel production techniques for Mo-99, such as accelerator-based and LEU (low enriched uranium)-based production (e.g. neutron capture, cyclotrons, linear accelerators) start to replace high neutron flux reactors.
Country-wise Outlook
United States
The United States molybdenum-99 market is characterized by robust and sustained growth, supported by the increasing demand for other diagnostic imaging procedures type including SPECT (Single Photon Emission Computed Tomography). Mo‐99 is necessary for production of Technetium‐99m (Tc‐99m) for use in over 80% of nuclear medicine diagnostic applications.
Growth is further fueled by efforts by the USA Department of Energy (DOE) and the National Nuclear Security Administration (NNSA) to develop domestic, non-HEU (highly enriched uranium) Mo-99 production capacities. It also hopes to scale production of its own isotope production reactors to give it autonomy over their supply.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 4.9% |
United Kingdom
With growth in nuclear medicine procedures driven chiefly by the NHS, particularly in the fields of oncology and cardiology diagnostics, the UK Molybdenum-99 market continues to show healthy growth. The UK is not a domestic producer of Mo-99, but strong links with European suppliers and the planned investment in radiopharmaceutical infrastructure are contributing to the advancement of supply security. Rapid adoption of SPECT/CT technologies and increasing need for reliable isotope availability is to drive the market significantly.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 4.4% |
European Union
Countries such as the Netherlands, Belgium, and France are also some of the leading producers and suppliers of this isotope in the world, making the EU Molybdenum-99 market a strong one. EU enjoys mature nuclear medicine infrastructure along with government-backed initiatives for modernizing isotope production with low-enriched uranium (LEU).
As reactors are continuously modernized and investments in alternate production techniques like accelerator-based Mo-99 are made, supply reliability and medical isotope shortages are expected to improve.
| Region | CAGR (2025 to 2035) |
|---|---|
| EU | 4.3% |
Japan
The molybdenum-99 market in Japan is growing, driven by increasing demand for nuclear imaging in the diagnosis of cancer and cardiovascular diseases. Japan had historically relied on imported sources for Mo-99, but is seeking domestic supply solutions through use of LEU and accelerators.
Market stability is supported by government support for the expansion of nuclear medicine and the effort to reduce dependence on aging reactors. And the proliferation of private imaging centers, as well as hospital nuclear medicine departments, is driving demand.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 4.6% |
South Korea
The molybdenum-99 market of South Korea is increasing steadily, underpinned by a robust nuclear tech foundation and governmental moves to advance the radiopharmaceutical market. The country is making investments in domestic Mo-99 production capabilities to reduce reliance on imports and increase supply security. The rise in the prevalence of lifestyle diseases in an older population with more of a focus on oncology and a strong healthcare infrastructure is bolstering demand for diagnostic imaging.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 4.5% |
Scope of Report on Molybdenum-99 Market
| Report Attributes | Details |
|---|---|
| Current Total Market Size (2025) | USD 5.17 billion |
| Projected Market Size (2035) | USD 7.74 billion |
| CAGR (2025 to 2035) | 4.6% |
| Base Year for Estimation | 2024 |
| Historical Period | 2020 to 2024 |
| Projections Period | 2025 to 2035 |
| Market Analysis Parameters | Revenue in USD billion/ Volume in curies |
| By Isotopic Application | SPECT and Gamma Camera |
| By End User | Hospitals and Diagnostic Centers |
| Regions Covered | North America, Latin America, East Asia, South Asia & Pacific, Eastern Europe, Western Europe, Middle East & Africa |
| Countries Covered | United States, Japan, Germany, India, United Kingdom, France, Italy, Brazil, Canada, South Korea, Australia, Spain, Netherlands, Saudi Arabia, Switzerland |
| Key Players | Curium Company, Eckert & Ziegler Holding Company, Shine Medical Technologies, NTP Radioisotopes SOC Ltd., North Star Medical Radioisotopes LLC, JSC Isotope, ANSTO, Lantheus Medical Imaging Inc., IRE ELiT, Niowave Inc. |
| Additional Attributes | Dollar sales by value, market share analysis by region, country-wise analysis |
| Customization and Pricing | Available upon request |
Segmentation
By Isotopic Application:
- SPECT
- Gamma Camera
By End User:
- Hospitals
- Diagnostic Centers
By Region:
- North America
- Latin America
- East Asia
- South Asia & Pacific
- Eastern Europe
- Western Europe
- Middle East & Africa
Frequently Asked Questions
What was the overall size of the molybdenum-99 market in 2025?
The overall market size for molybdenum-99 market was USD 5.17 billion in 2025.
How big the molybdenum-99 market is expected in 2035?
The molybdenum-99 market is expected to reach USD 7.74 billion in 2035.
What will drive the demand for molybdenum-99 market during the forecast period?
Rising demand for medical imaging procedures, increasing prevalence of chronic diseases, and growing use of Mo-99 in diagnostic radiopharmaceuticals will drive market growth.
List the top 5 countries contributing in molybdenum-99 market?
The top 5 countries which drives the development of molybdenum-99 market are USA, European Union, Japan, South Korea and UK.
Which segment in type is expected to lead molybdenum-99 market?
SPECT imaging expected to grow to command significant share over the assessment period.
Table of Content
- Executive Summary
- Industry Introduction, including Taxonomy and Market Definition
- Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- Global Market Demand Analysis 2020 to 2024 and Forecast 2025 to 2035, including Historical Analysis and Future Projections
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035
- Isotopic Application
- End User
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Isotopic Application
- SPECT
- Gamma Camera
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By End User
- Hospitals
- Diagnostic Centers
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Region
- North America
- Latin America
- East Asia
- South Asia & Pacific
- Eastern Europe
- Western Europe
- Middle East & Africa
- North America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Latin America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- East Asia Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- South Asia & Pacific Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Eastern Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Western Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Middle East & Africa Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Sales Forecast 2025 to 2035 by Isotopic Application and End User for 30 Countries
- Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- Company Profile
- Curium Company
- Eckert & Ziegler Holding Company
- Shine Medical Technologies
- NTP Radioisotopes SOC Ltd.
- North Star Medical Radioisotopes LLC
- JSC Isotope
- ANSTO (Australian Nuclear Science and Technology Organisation)
- Lantheus Medical Imaging Inc.
- IRE ELiT
- Niowave Inc.
